Lipella Pharmaceuticals (LIPO) Competitors $0.60 -0.04 (-6.34%) As of 01:16 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LIPO vs. LPTX, SNGX, EPIX, HOOK, MRKR, GOVX, SNSE, MBIO, PHXM, and ERNAShould you be buying Lipella Pharmaceuticals stock or one of its competitors? The main competitors of Lipella Pharmaceuticals include Leap Therapeutics (LPTX), Soligenix (SNGX), ESSA Pharma (EPIX), HOOKIPA Pharma (HOOK), Marker Therapeutics (MRKR), GeoVax Labs (GOVX), Sensei Biotherapeutics (SNSE), Mustang Bio (MBIO), PHAXIAM Therapeutics (PHXM), and Ernexa Therapeutics (ERNA). These companies are all part of the "pharmaceutical products" industry. Lipella Pharmaceuticals vs. Its Competitors Leap Therapeutics Soligenix ESSA Pharma HOOKIPA Pharma Marker Therapeutics GeoVax Labs Sensei Biotherapeutics Mustang Bio PHAXIAM Therapeutics Ernexa Therapeutics Lipella Pharmaceuticals (NASDAQ:LIPO) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations. Does the media prefer LIPO or LPTX? In the previous week, Lipella Pharmaceuticals had 1 more articles in the media than Leap Therapeutics. MarketBeat recorded 2 mentions for Lipella Pharmaceuticals and 1 mentions for Leap Therapeutics. Leap Therapeutics' average media sentiment score of 1.89 beat Lipella Pharmaceuticals' score of 0.50 indicating that Leap Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Lipella Pharmaceuticals Positive Leap Therapeutics Very Positive Which has better valuation and earnings, LIPO or LPTX? Lipella Pharmaceuticals has higher revenue and earnings than Leap Therapeutics. Leap Therapeutics is trading at a lower price-to-earnings ratio than Lipella Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLipella Pharmaceuticals$536.36K5.17-$5.02M-$3.43-0.17Leap TherapeuticsN/AN/A-$67.56M-$1.58-0.20 Is LIPO or LPTX more profitable? Leap Therapeutics has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Lipella Pharmaceuticals' return on equity of -224.08% beat Leap Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lipella Pharmaceuticals-988.83% -224.08% -172.88% Leap Therapeutics N/A -237.65%-155.38% Do analysts rate LIPO or LPTX? Leap Therapeutics has a consensus target price of $3.38, suggesting a potential upside of 963.33%. Given Leap Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Leap Therapeutics is more favorable than Lipella Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipella Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Leap Therapeutics 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility and risk, LIPO or LPTX? Lipella Pharmaceuticals has a beta of -0.1, indicating that its share price is 110% less volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of -0.21, indicating that its share price is 121% less volatile than the S&P 500. Do institutionals and insiders have more ownership in LIPO or LPTX? 74.3% of Lipella Pharmaceuticals shares are held by institutional investors. Comparatively, 30.5% of Leap Therapeutics shares are held by institutional investors. 32.1% of Lipella Pharmaceuticals shares are held by company insiders. Comparatively, 7.5% of Leap Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryLipella Pharmaceuticals beats Leap Therapeutics on 8 of the 14 factors compared between the two stocks. Get Lipella Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LIPO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LIPO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIPO vs. The Competition Export to ExcelMetricLipella PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.77M$3.08B$5.69B$10.27BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-0.1521.3075.8626.51Price / Sales5.17379.80489.92165.32Price / CashN/A44.4425.8129.89Price / Book0.389.6112.846.32Net Income-$5.02M-$53.28M$3.28B$270.51M7 Day Performance-6.34%0.30%0.20%2.15%1 Month Performance-4.76%4.57%4.59%6.35%1 Year Performance-82.48%9.23%68.31%25.48% Lipella Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIPOLipella Pharmaceuticals2.0215 of 5 stars$0.60-6.3%N/A-81.4%$2.77M$536.36K-0.154News CoverageShort Interest ↓Gap DownLPTXLeap Therapeutics2.7286 of 5 stars$0.28-1.2%$3.38+1,095.1%-88.7%$11.70MN/A-0.1840Positive NewsSNGXSoligenix2.7498 of 5 stars$2.68+0.8%$6.00+123.9%-23.8%$11.49MN/A-0.7120Positive NewsShort Interest ↓Gap UpEPIXESSA Pharma3.0421 of 5 stars$0.24+1.3%$2.00+733.3%-97.2%$11.35MN/A-0.4350Dividend AnnouncementHOOKHOOKIPA Pharma3.0733 of 5 stars$0.92+2.2%$4.50+389.3%-81.4%$11.21M$9.35M-0.16160Positive NewsShort Interest ↓Gap DownMRKRMarker Therapeutics3.6446 of 5 stars$0.85-2.7%$13.17+1,447.2%-65.9%$11.01M$6.59M-0.6260GOVXGeoVax Labs1.8191 of 5 stars$0.69-1.2%$8.50+1,133.7%-75.8%$10.98M$3.95M-0.3410News CoverageShort Interest ↑SNSESensei Biotherapeutics4.7032 of 5 stars$8.49+7.0%$55.00+548.2%-18.5%$10.69MN/A-0.4040Positive NewsShort Interest ↓Gap UpMBIOMustang Bio1.0203 of 5 stars$1.47+8.1%N/A-88.3%$10.64MN/A-0.02100Positive NewsPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049ERNAErnexa Therapeutics0.931 of 5 stars$1.27+2.0%N/A-94.8%$9.70M$580K-0.1510News Coverage Related Companies and Tools Related Companies LPTX Competitors SNGX Competitors EPIX Competitors HOOK Competitors MRKR Competitors GOVX Competitors SNSE Competitors MBIO Competitors PHXM Competitors ERNA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LIPO) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredFanatics Hit $31B-Is This Nasdaq Next?Fanatics built an empire by owning the fan experience-scaling to a $31B valuation. But the next wave isn't abo...i2i Marketing Group, LLC | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored$4?In times like these… it’s almost impossible to find a good deal. That’s why you should check this out. G...Monument Traders Alliance | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipella Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipella Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LIPO Stock Alerts